MDA-MB-231-derived exosomes releasing miR-454 disrupted the Wnt pathway by targeting PRRT2, thereby promoting the biological properties of cancer stem cells (CSCs) in vitro and ovarian cancer cell growth in vivo (43). The gene discussed is PRRT2; the disease is cancer.